Nialamide

Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.[2][3]

Nialamide

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	N06AF02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)
Identifiers
IUPAC name N-benzyl-3-(N-(pyridine-4-carbonyl)hydrazino)propanamide
CAS Number	51-12-7
PubChem CID	4472
DrugBank	DB04820
ChemSpider	4317
UNII	T2Q0RYM725
KEGG	D07337
CompTox Dashboard (EPA)	DTXSID1023362
ECHA InfoCard	100.000.073
Chemical and physical data
Formula	C16H18N4O2
Molar mass	298.346 g·mol^−1
3D model (JSmol)	Interactive image
SMILES O=C(NNCCC(=O)NCc1ccccc1)c2ccncc2
InChI InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22) Key:NOIIUHRQUVNIDD-UHFFFAOYSA-N
(verify)

The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.[4]

See also

• Hydrazine (antidepressant)

References

1. William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
2. Gad SC (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
3. Shorter E (28 September 2008). Before Prozac: The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
4. Bencze WL, Hess R, DeStevens G (6 December 2012). "Hypolipidemic agents". Progress in Drug Research. Fortschritte der Arzneimittelforschung. Progrès des Recherches Pharmaceutiques. Springer Science & Business Media. 13: 217–92. doi:10.1007/978-3-0348-7068-9_5. ISBN 9783642661907. PMID 4982663. Retrieved 3 October 2017.